Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Apr 2017 | FROM EXTERNAL EXPERTS

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Nov 2016 | FROM EXTERNAL EXPERTS

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function

Jan 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Nov 2015 | FROM EXTERNAL EXPERTS

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.